• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said a preclinical study of its influenza DNA vaccine against the newly emergent virulent H7N9 flu virus showed that the vaccine achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes.